Evidence map›Paper›PMID 42453399›Full record

ReviewActa pharmaceutica Sinica. B2026

Xu Shi, Yue Zhao, Yunkai Tang, Gang Fu, Chen Qian, Feng Li, Zheyu Yang, Wenguo Cui, Wei Cai

Abstract readReview
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xu ShiDepartment of General Surgery, Shanghai Jiao Tong University School of Medicine affiliated Ruijin Hospital, Shanghai 200025, China.
Yue ZhaoDepartment of General Surgery, Shanghai Jiao Tong University School of Medicine affiliated Ruijin Hospital, Shanghai 200025, China.
Yunkai TangDepartment of Orthopaedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Gang FuDepartment of General Surgery, Shanghai Jiao Tong University School of Medicine affiliated Ruijin Hospital, Shanghai 200025, China.
Chen QianDepartment of General Surgery, Shanghai Jiao Tong University School of Medicine affiliated Ruijin Hospital, Shanghai 200025, China.
Feng LiDepartment of General Surgery, Shanghai Jiao Tong University School of Medicine affiliated Ruijin Hospital, Shanghai 200025, China.
Zheyu YangDepartment of General Surgery, Shanghai Jiao Tong University School of Medicine affiliated Ruijin Hospital, Shanghai 200025, China.
Wenguo CuiDepartment of Orthopaedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Wei CaiDepartment of General Surgery, Shanghai Jiao Tong University School of Medicine affiliated Ruijin Hospital, Shanghai 200025, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA therapy represents an innovative approach for cancer treatment, with several RNA-based therapeutics having received approval from the US Food and Drug Administration. Circular RNA (circRNA), a closed-loop RNA molecule characterized by its high stability, plays a significant role in regulating biological processes by modulating gene expression and facilitating protein translation. Given its unique structure and diverse functionalities, the delivery of exogenous circRNA has emerged as a novel strategy for cancer therapy. This review examines the mechanism underlying circRNA-mediated tumor therapy, emphasizing its various biological roles, including that of an RNA sponge, aptamer, gene editing tool, and facilitator of protein translation, and explores the therapeutic potential in oncology. The review provides a comprehensive discussion on the synthesis strategies of exogenous circRNA, based on T4 DNA ligase and the permuted introns-exons (PIE) method, as well as elucidating the purification techniques. This article also reviews prominent carriers currently employed for circRNA delivery, such as lipid nanoparticle (LNP), exosomes, and virus-like particle (VLP), with a particular emphasis on their application in cancer-targeted therapies. Finally, the review summarizes key challenges currently in the field along with viable solutions. It highlights the prospective role of artificial intelligence in enhancing circRNA delivery to facilitate precise cancer treatment based on exogenous circRNA.

Indexed as

Artificial intelligenceCancer therapyCancer vaccinesCircular RNA (circRNA)NanomedicinePrecision medicineRNA synthesisTargeted delivery

Identifiers

PMID42453399
PMCPMC13366352

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.